GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 by Xiong, Yulan et al.
GTPase Activity Plays a Key Role in the Pathobiology of
LRRK2
Yulan Xiong1,2, Candice E. Coombes3, Austin Kilaru4, Xiaojie Li1,2, Aaron D. Gitler4, William J. Bowers5,
Valina L. Dawson1,2,6,7, Ted M. Dawson1,2,7*, Darren J. Moore1,2,8*
1NeuroRegeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America,
2Departments of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 3Department of Molecular Biology and
Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 4Department of Cell and Developmental Biology, University of
Pennsylvania, Philadelphia, Pennsylvania, United States of America, 5Center for Neural Development and Disease, Department of Neurology, University of Rochester
Medical Center, Rochester, New York, United States of America, 6Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United
States of America, 7 Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 8 Brain
Mind Institute, School of Life Sciences, E´cole Polytechnique Fe´de´rale de Lausanne, Lausanne, Switzerland
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial
Parkinson’s disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple
domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease
through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces
toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced
neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not
well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker’s yeast
Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing
fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely
associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar
toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in
primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity
induced by human a-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast
including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by
expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that
the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed
at attenuating LRRK2-mediated neurodegeneration.
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Introduction
Parkinson’s disease (PD (OMIM #168600)) is a common
neurodegenerative movement disorder that is characterized by
muscular rigidity, bradykinesia, resting tremor and postural instability
[1,2]. Although typically a sporadic disease, mutations in the leucine-
rich repeat kinase 2 (LRRK2, PARK8, OMIM #607060, GenBank
#AY792511) gene have been identified as a cause of late-onset,
autosomal dominant familial PD that is clinically and neurochem-
ically indistinguishable from sporadic PD [3–7]. Importantly, LRRK2
pathogenic mutations also contribute to sporadic PD [4,8]. Mutations
in LRRK2 are the most common cause of familial and sporadic PD
identified to date [9]. The LRRK2 gene encodes a large protein of
2527 amino acids that contains multiple domains. These include a
LRRK2-specific repeat region, multiple leucine-rich repeats, a Ras of
Complex (Roc) GTPase domain, a C-terminal of Roc (COR) domain,
and a protein kinase domain belonging to the tyrosine kinase-like
protein kinase family [10,11]. LRRK2 exhibits kinase activity
whereby it can undergo autophosphorylation and can phosphorylate
generic substrates [12–18]. However, physiological substrates for the
kinase activity of LRRK2 have not yet been identified. The GTPase
domain of LRRK2 can mediate GDP (guanosine-59-diphosphate)/
GTP (guanosine-59-triphosphate) binding as well as GTP hydrolysis
albeit at a relatively slow rate compared to other small GTPases such
as Ras [14,15,19–22]. Intriguingly, GTP binding markedly enhances
the kinase activity of LRRK2 and is an essential requirement for
kinase activity [14,15,21,22]. It is unclear at present how the GTP
binding and GTP hydrolysis activities of LRRK2 are regulated.
Disease-associated mutations located throughout the LRRK2 protein
have been shown to variably alter GTP binding, GTP hydrolysis or
PLoS Genetics | www.plosgenetics.org 1 April 2010 | Volume 6 | Issue 4 | e1000902
kinase activity [14–24]. Thus, alterations in both GTPase and protein
kinase activity are clearly important for the development of PD due to
LRRK2 mutations.
A number of useful models have been developed to investigate
the pathobiology of LRRK2 disease-associated variants, including
Drosophila, transgenic mice and primary neuronal models. Studies
in cultured primary cortical neurons reveal that the exogenous
expression of pathogenic mutant forms of full-length human
LRRK2 (i.e. G2019S, R1441C and Y1699C) induces marked
neuronal toxicity relative to the wild-type protein [21–23]. Wild-
type LRRK2 can also induce neuronal toxicity but to a lesser
degree. LRRK2-induced toxicity in this neuronal model is
dependent on intact GTP binding and kinase activity [21–23].
In Drosophila models, expression of human LRRK2 variants
induces selective dopaminergic neurodegeneration and motor
dysfunction [25–27]. Mutant LRRK2 R1441G BAC transgenic
and R1441C knock-in mice exhibit mild defects in dopaminergic
neurotransmission and motor deficits [28,29]. These observations
are consistent with a toxic gain-of-function mechanism for disease-
associated LRRK2 variants. The molecular mechanism(s) and/or
pathway(s) by which LRRK2 variants induce neuronal toxicity are
poorly understood and how alterations in GTPase or kinase
activities regulate the toxic effects of LRRK2 are not well defined.
Model organisms including yeast, worms, flies and mice are
commonly used to uncover the fundamental biology and pathobiology
of proteins associated with neurodegenerative diseases, including poly-
glutamine expansion disorders, Parkinson’s disease, Alzheimer’s
disease, Prion diseases and Friedreich’s ataxia. The baker’s yeast
Saccharomyces cerevisiae, a eukaryotic single-cell organism, provides a
powerful experimental system in which to dissect complex biological
pathways and processes. Major advantages of yeast include the high
degree of conservation of pathways, processes and protein function
with mammalian cells, and the accessibility of yeast cells to genetic
manipulation and genome-wide screening approaches. For Parkinson’s
disease (PD), yeast have provided unique insight into the basic biology
and pathobiology of the a-synuclein protein that is associated with
autosomal dominant familial PD [30–33]. Here, we have employed
yeast as a model to further understand the basic pathobiology of
LRRK2. Expression of truncated human LRRK2 reduces yeast
viability in a manner largely dependent on the GTPase domain of this
protein. Reduced viability in this yeast LRRK2 model is independent
of kinase activity and disease-associated mutations, but can be
modulated instead by altering GTPase activity and is associated with
defects in vesicular trafficking and autophagy. This yeast model
provides insight into the basic pathobiology of LRRK2 and suggests
that the GTPase domain may contribute to the cellular toxicity of
LRRK2. These findings may guide future therapeutic strategies aimed
at attenuating LRRK2-mediated neurodegeneration.
Results
Expression of Human LRRK2 Domain Fragments Reduces
Yeast Viability
To gain novel insight into the pathobiology of LRRK2, we set out
to develop a simple yeast LRRK2 model. Yeast cells were
transformed with expression constructs that express at high copy
V5-tagged full-length human LRRK2 under the control of the
galactose-inducible GAL1 promoter. Expression of wild-type (WT)
or G2019S LRRK2 variants fail to affect the viability of yeast cells,
which is most likely due to the formation of large LRRK2-positive
intracytoplasmic inclusions that are biochemically insoluble (Figure
S1). The same results are observed with low copy expression
constructs (Figure S1). Thus, we elected to examine the detrimental
effects of various smaller protein fragments of human LRRK2 that
contain different functional domains.
Following galactose induction of high copy expression constructs,
LRRK2 fragments minimally containing the GTPase domain
markedly reduce yeast viability relative to control cells, with the
most toxic fragment containing the central GTPase, COR and kinase
domains (GTP-COR-Kin) of LRRK2 (Figure 1A). A larger LRRK2
fragment additionally containing the C-terminus (GTP-COR-Kin-
CT) reduces yeast viability to a similar extent. The GTPase domain
alone is also sufficient to markedly reduce yeast viability (Figure 1A).
LRRK2 fragments containing the kinase domain alone (Kin or Kin-
CT) or a fragment lacking the N-terminal region (DN-LRRK2),
which is poorly expressed, are much less toxic to yeast (Figure 1A).
Western blot analysis confirms the expression of each LRRK2
fragment in yeast following galactose induction (Figure 1B). LRRK2
fragments exhibit similar diffuse cytoplasmic localization patterns in
yeast as revealed by fluorescence microscopy (Figure S2). The loss of
viability due to the expression of each LRRK2 fragment is confirmed
by monitoring the growth rate of yeast cells in liquid media following
galactose induction (Figure 1C).
We focused further on the GTP-COR-Kin fragment of LRRK2
throughout this study since its expression is most toxic to yeast cells
and because it permits further analysis of the contribution of both
enzymatic domains. To test if the toxicity is dose-dependent, we
also examined the effects of low copy expression of the GTP-
COR-Kin fragment. A similar phenotype is observed as with high
copy expression of the GTP-COR-Kin fragment (Figure 1A and
1C). Thus, the protein length, expression levels or cellular
localization of each LRRK2 fragment do not correlate with their
effects on yeast viability suggesting that alterations in viability are
dependent on the protein domain composition or activity of each
LRRK2 fragment. Moreover, these data demonstrate that
LRRK2 protein fragments that contain the GTPase domain, but
not full-length LRRK2, can reduce the viability of yeast cells.
GTPase Activity Modulates LRRK2-Induced Toxicity in
Yeast
Since expression of the GTPase domain of LRRK2 is sufficient to
markedly reduce yeast viability, we sought to determine whether
Author Summary
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. PD is considered to be caused
by a combination of risk factors including environmental
exposure, age, and a positive family history for disease.
Several genes have been unambiguously implicated in PD.
However, our knowledge is still limited about these genes
and the disease mechanisms involved. Mutations in the
LRRK2 gene account for up to 40% of PD in certain
populations. Since a single-cell model, baker’s yeast, has
been employed successfully to study the function of genes
related to PD and other neurodegenerative disorders, we
developed a yeast model of LRRK2 cytotoxicity in this
study to investigate the function of LRRK2. We dissected
the LRRK2 protein into different fragments including the
various functional domains and found that fragments
including the GTPase domain of LRRK2 are toxic. This
toxicity can be modulated by alterations in GTPase activity
and correlates with defects in cellular trafficking. These
truncated LRRK2 variants induce similar toxicity and
trafficking defects in both yeast and primary neuronal
models. This yeast model reveals an important role of
GTPase activity in the basic pathobiology of LRRK2 and
may guide future therapeutic strategies for PD.
GTPase Activity and LRRK2 Toxicity
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alterations in GTPase activity could influence this growth deficit. A
number of missense mutations were introduced into the GTPase
domain within the GTP-COR-Kin LRRK2 fragment that are
predicted to functionally alter enzymatic activity (Figure 2A). Two
mutations, K1347A and T1348N, disrupt the conserved guanine
nucleotide phosphate-binding loop motif (P-loop, residues 1341–
1348) and prevent GDP/GTP binding to the GTPase domain
[15,22]. Two other mutations, R1398L and R1398Q, were targeted
at the R1398 residue, a highly conserved glutamine residue in most
small GTPases (i.e. Q61 in H-Ras). LRRK2 contains a highly
conserved DFAGR motif (residues 1394–1398) in the switch II
region which is mainly responsible for GTP hydrolysis. The P-loop
residue T1343 is a glycine residue (G12) in H-Ras. In H-Ras, the
combined G12V and Q61L mutations create a GTPase-inactive
form of this protein, which is constitutively GTP-bound and active.
We introduced these two key H-Ras residues into LRRK2 via the
analogous mutations T1343G and R1398Q (RQ/TG) to create a
Ras-like GTPase that leads to increased GTP hydrolysis activity
(Figure 2A) [15]. Moreover, a common R1441C pathogenic variant
was also introduced into the GTPase domain of LRRK2.
Expression of the GTP-COR-Kin fragment of LRRK2 containing
each mutation was induced by spotting yeast cells onto galactose
media. Remarkably, altering the GTPase activity of LRRK2 leads
to marked changes in yeast viability (Figure 2B). Compared to WT
LRRK2, the GTP binding-deficient mutants K1347A and T1348N
cause a dramatic reduction in yeast viability whereas the mutant
R1398L and Ras-like mutant RQ/TG partially improve viability
(Figure 2B). The disease-associated R1441C variant reduces yeast
viability similar to WT LRRK2 (Figure 2B). Western blot analysis
reveals that each mutant LRRK2 fragment is expressed at similar
levels, which excludes alterations in expression level as a cause of
their differential effects on yeast viability (Figure 2C). Furthermore,
fluorescence microscopic analysis fails to reveal obvious differences
in the cellular localization of truncated LRRK2 GTPase variants
Figure 1. Expression of LRRK2 domain fragments reduces the viability of yeast. (A) LRRK2 domain fragments reduce yeast viability. Yeast
cells (BY4741 MATa) were transformed with galactose-inducible high copy expression constructs containing the following human LRRK2 domain
fragments: GTPase domain (GTP, residues 1300–1514), kinase domain (Kin, residues 1843–2163), kinase domain plus the C-terminal region (Kin-CT,
residues 1843–2527), GTPase-COR-kinase domains (GTP-COR-Kin, residues 1300–2163), GTPase-COR-kinase domains plus the C-terminal region (GTP-
COR-Kin-CT, residues 1300–2527), and a LRRK2 fragment lacking the N-terminal LRRK2-specific repeat region (DN-LRRK2, residues 570–2527) and low
copy expression construct containing the GTP-COR-Kin region. Empty vectors (pYES/CT, p416GAL) are used as controls. Cells were spotted onto
media containing glucose (LRRK2 Off, repressed, left panel) or galactose (LRRK2 On, induced, right panel) and incubated at 30uC for 2–3 days. Shown
are five-fold serial dilutions (from left to right, as indicated by graded open box) starting with equal numbers of cells. Protein domain structure of
each LRRK2 fragment relative to the full-length protein is also indicated. (B) Expression of LRRK2 domain fragments in yeast cells following galactose
induction was detected by Western blot analysis with anti-V5 antibody, with anti-PGK antibody as a protein loading control. (C) Growth curve analysis
in liquid media containing galactose was used to monitor the growth rate of yeast cells expressing each LRRK2 domain fragment or with empty
vector as a control. Data are taken from three independent experiments with each data point representing the mean 6 SEM (n=3).
doi:10.1371/journal.pgen.1000902.g001
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Figure 2. GTPase activity modulates LRRK2-induced toxicity in yeast. (A) Table of LRRK2 sequence variants employed in this study and their
predicted functional effects. (B) GTPase mutations, K1347A and T1348N, markedly enhance LRRK2-induced toxicity in yeast compared to WT or other
GTPase mutations. Yeast cells were transformed with galactose-inducible expression constructs containing the central GTP-COR-Kin fragment of
LRRK2 harboring various functional GTPase variants (WT, R1441C, R1398L, R1398Q/T1343G, K1347A, and T1348N) or empty vector as a control.
Spotting experiments were conducted to examine the viability of yeast cells due to the expression of each truncated LRRK2 GTPase variant. Shown
are five-fold serial dilutions (from left to right, as indicated by graded open box) starting with equal numbers of cells grown on media containing
glucose (LRRK2 Off, left panel) or galactose (LRRK2 On, right panel). (C) Expression of LRRK2 GTPase variants in the GTP-COR-Kin fragment in yeast
following galactose induction was detected by Western blot analysis with anti-V5 antibody, with anti-PGK antibody as control for protein loading. (D)
Growth curve analysis in liquid media containing galactose was used to measure the growth rate of yeast cells expressing each truncated LRRK2
GTPase variant relative to an empty vector control. Data are taken from three independent experiments with each data point representing the mean
6 SEM (n=3). (E) GTP-binding activity was determined for each LRRK2 GTPase variant (in the GTP-COR-Kin fragment) derived from yeast cell lysates
following galactose induction by measuring the relative levels of GTP-bound LRRK2 with normalization to input levels of total LRRK2. LRRK2 levels
GTPase Activity and LRRK2 Toxicity
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with each variant adopting a similar diffuse cytoplasmic distribu-
tion in yeast cells (Figure S2). Growth impairments induced by
expression of each mutant LRRK2 fragment in yeast are
further confirmed in liquid media following galactose induction
(Figure 2D).
To determine how alterations in the GTPase activity of LRRK2
due to each functional mutation correlate with changes in yeast
viability, we examined both the GTP binding and GTP hydrolysis
activities of each mutant LRRK2 fragment. GTP binding was
measured using an established GTP-sepharose pull-down assay on
total yeast proteins expressing each LRRK2 fragment (Figure 2E).
WT and the disease-associated mutant R1441C LRRK2 bind to
immobilized GTP to similar extents whereas surprisingly all other
mutants exhibit significantly reduced GTP binding (Figure 2E).
Consistent with prior reports of full-length LRRK2 [14,15,19–22],
the P-loop mutations, T1348N and K1347A, impair the GTP
binding of LRRK2 (Figure 2E). Importantly, the GTP binding
capacity of each LRRK2 GTPase mutant does not correlate with
its effects on yeast viability. It is not currently possible to measure
the capacity of each mutant LRRK2 fragment to bind GDP. It is
likely that certain mutations (i.e. the P-loop mutants K1347A and
T1348N) impair GDP/GTP binding whereas other mutations (i.e.
the Ras-like mutant RQ/TG and R1398L) may alter the affinity
for binding to GDP and GTP.
The effects of each mutation on LRRK2-mediated GTP
hydrolysis were also determined in vitro by measuring the release
of the c-phosphate moiety from GTP (Figure 2F). Truncated WT
LRRK2 displays detectable GTP hydrolysis activity whereas the
R1441C mutant exhibits a small reduction in activity, similar to
previous reports [14,19,20]. As expected, the Ras-like RQ/TG
mutant leads to a marked increase in GTP hydrolysis activity but
unexpectedly the R1398L mutant produces a similar increase in
activity. The P-loop mutants K1347A and T1348N essentially
abolish the GTP hydrolysis activity of LRRK2 as expected
(Figure 2F). Therefore, alterations in GTP hydrolysis activity of
each truncated LRRK2 GTPase mutant correlate closely with their
effects on yeast viability. In this case, increased GTP hydrolysis
partially improves the viability of yeast compared to WT LRRK2
whereas impaired hydrolysis dramatically reduces yeast viability.
Notably, alterations in kinase activity via introduction of kinase-
impaired (i.e. K1906M or T2031A/S2032A/T3035A) or a kinase-
hyperactive (i.e. G2019S) mutation fails to similarly influence
LRRK2-induced toxicity in yeast (Figure S3).
To further examine if GTPase activity plays a key role in the
toxic process, we investigated the GTPase activity of full-length
human LRRK2 harboring the most frequent mutations causing
PD. Importantly, the mutations R1441C/G in the GTPase
domain and Y1699C in the adjacent COR domain, significantly
decrease GTPase activity (Figure 2G) although the mutations,
G2019S and I2020T, in the kinase domain do not have a
significant effect, suggesting that impaired GTP hydrolysis of
LRRK2 can contribute to PD.
Expression of LRRK2 Causes Defects in Endocytic
Vesicular Trafficking and Autophagy
In yeast cells expressing human a-synuclein (SNCA, PARK1/4,
OMIM #163890, GenBank #BC108275), defects in vesicular
trafficking have been shown to underlie the cytotoxic effects of this
protein with the earliest defect being a block in ER-to-Golgi
vesicular trafficking [30–32]. Since a-synuclein pathology is a
common feature of patients with LRRK2 mutations [3,7,34],
vesicular trafficking was examined to determine whether similar
defects could also underlie LRRK2-induced toxicity in yeast. The
lipophilic fluorescent dye, FM4–64, is useful for monitoring
endocytosis in yeast. FM4–64 binds to the plasma membrane of
yeast cells where it is internalized by endocytosis into vesicles that
subsequently undergo trafficking to the vacuole via the early and
late endosome compartments. Thus, FM4–64 dye selectively stains
the yeast vacuolar membrane appearing as a large ring-like
cytoplasmic structure.
Yeast cells expressing truncated LRRK2 variants following
galactose induction were incubated with FM4–64 dye and live-cell
imaging was conducted by confocal fluorescence microscopy.
WT LRRK2 expression partly disrupts the normal trafficking of
FM4–64 to the vacuolar membrane relative to control cells, which
exhibit normal ring-like vacuolar staining (Figure 3A). WT
LRRK2 expression results in the appearance of large cytoplasmic
punctate structures in addition to normal vacuolar staining,
suggesting a modest defect in trafficking of FM4–64-labeled
vesicles to the vacuole leading to their accumulation in endosomes.
Yeast cells expressing truncated LRRK2 containing the two most
toxic GTPase mutations, K1347A and T1348N, which impair the
GTP binding and hydrolysis activity of LRRK2, exhibit severe
defects in the endocytic trafficking pathway with a dramatic
increase in the appearance of labeled punctate structures and the
complete absence of normal vacuolar membrane staining
(Figure 3A). Truncated LRRK2 variants that partially improved
yeast viability compared to WT protein (i.e. RQ/TG and
R1398L) induce similar trafficking defects to WT LRRK2
(Figure 3A). Normal FM4–64 labeling of vacuolar membranes is
observed when yeast cells are grown in glucose media (data not
shown). DIC images show that cells expressing each of the
LRRK2 fragments have normal vacuolar morphology (Figure 3D).
Quantitation of defective endocytic trafficking reveals that the
toxic GTPase-inactive mutants, K1347A and T1348N, lead to a
significant increase in the number and frequency of FM4–64-
labeled punctate structures per cell compared to WT LRRK2,
whereas the GTPase-active mutants, RQ/TG and R1398L,
display a small non-significant reduction in the number of
punctate structures relative to WT (Figure 3B and 3C). Punctate
structures are not normally observed in control yeast cells
(Figure 3B and 3C). The vesicular trafficking defects induced by
expression of each truncated LRRK2 GTPase variant in yeast do
not correlate with alterations in their cellular localization (Figure
S2). In particular, there is no specific enrichment in the vacuole or
were determined from western blot images by densitometric analysis. Data are expressed as GTP-binding as a percent of WT LRRK2 levels with each
bar representing the mean 6 SEM from three independent experiments. An example Western blot probed with anti-V5 antibody is shown indicating
the levels of GTP-bound GTP-COR-Kin LRRK2 fragment and input levels. (F) GTP hydrolysis activity was determined in yeast by measuring the
concentration of free Pi released from GTP for each truncated LRRK2 GTPase variant and normalized to LRRK2 input levels. Input levels of
immunoprecipitated GTP-COR-Kin LRRK2 derived from yeast total lysates were detected by Western blot analysis with anti-V5 antibody, as shown,
with densitometric analysis. GTP hydrolysis activity for each LRRK2 variant is expressed as Pi release as a percent of WT LRRK2 activity with each bar
representing the mean 6 SEM from three independent experiments. (G) GTP hydrolysis activity was measured for disease-associated mutations in
full-length human LRRK2. Input levels of immunoprecipitated myc-tagged LRRK2 derived from HEK-293T cell lysates were detected by Western blot
analysis with anti-MYC antibody, as shown, with densitometric analysis. GTP hydrolysis activity for each LRRK2 variant is expressed as Pi release as a
percent of WT LRRK2 activity with each bar representing the mean 6 SEM from five independent experiments. Data were analyzed for statistical
significance by two-tailed unpaired Student’s t-test compared to WT-LRRK2 (*P,0.01 and **P,0.001). n.s., non-significant.
doi:10.1371/journal.pgen.1000902.g002
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endosomal compartments of each LRRK2 variant that would
obviously account for their differential effects on endocytic
vesicular trafficking (Figure S2). These results indicate that the
endocytic vesicular trafficking defect in yeast is associated with
alterations in LRRK2 GTPase activity and likely underlies toxicity
in yeast induced by truncated LRRK2.
To verify that the observed defects induced by LRRK2
expression in yeast are due to vesicular trafficking pathways rather
than simply by protein aggregation, yeast cells expressing
truncated LRRK2 variants following galactose induction were
examined by transmission electron microscopy (TEM) (Figure 4).
Interestingly, yeast cells expressing truncated LRRK2 containing
the two most toxic GTPase mutations, K1347A and T1348N,
which impair GTPase activity exhibit a significant increase of
autophagic vacuoles (AVs) (74.7% in K1347A cells and 86.2% in
T1348N cells) compared to WT LRRK2 (19.4% AVs) (Figure 4A
and 4B). In contrast, AVs were uncommon in yeast cells carrying
empty vector (9.2% AVs) (Figure 4A and 4B). In accordance with
fluorescence localization studies of truncated LRRK2 variants in
yeast (Figure S2), protein aggregates or inclusions were not readily
observed in the electron micrographs. Taken together these data
indicate that LRRK2-induced trafficking defects are mediated at
least in part by alterations in autophagy in addition to effects on
the endocytic vesicular trafficking pathway.
To provide insight into the mechanism of LRRK2-induced
toxicity in yeast, and to determine whether there are differences or
similarities with a-synuclein-induced toxicity, a small candidate
genetic screen was performed in yeast focused on modifiers of
a-synuclein-induced toxicity. We elected to analyze potent
modifiers of human a-synuclein-induced toxicity Ypt1 (GenBank
#AAS56793) and Ykt6 (GenBank #AAB32050) [30,31], as well
as Hsp31 (Genbank #AAB64972), the yeast ortholog of human
DJ-1 [33], a neuroprotective redox-responsive protein associated
with familial PD (PARK7, OMIM #606324) [35,36]. Yeast
cells were transformed with constructs expressing truncated WT
LRRK2, each candidate protein alone, or both proteins together
under the control of the GAL1 promoter and viability was
examined by spotting of yeast cells on to galactose media.
Expression of WT LRRK2 alone reduces yeast viability, whereas
co-expression with each of the three candidate proteins fails to
suppress the LRRK2-induced growth deficit (Figure S4). The
three candidate yeast proteins were also tested for their ability to
suppress toxicity due to the expression of the truncated LRRK2
variants, K1347A and T1348N, which induce a more pronounced
loss of viability in yeast than WT LRRK2. Co-expression with
each of the three candidate proteins also fails to suppress the
K1347A- or T1348N-induced growth deficit (Figure S4). Collec-
tively, our data demonstrate that known potent suppressors
of a-synuclein-induced toxicity in yeast (i.e. Ypt1 and Ykt6) do
not specifically suppress LRRK2-induced toxicity in this model
suggesting that a-synuclein and LRRK2 induce toxicity in yeast
through distinct pathways.
Following expression of truncated LRRK2 variants, we also fail
to observe defects in the normal trafficking of carboxypeptidase Y
Figure 3. LRRK2 GTPase variants induce defects in endocytic vesicular trafficking. (A) Endocytosis of the lipophilic fluorescent dye FM4–64
(red) was employed to monitor the effects of LRRK2 GTPase variants (in the GTP-COR-Kin fragment) on vesicular trafficking to the vacuole in yeast. Cells
carrying empty vector display normal ring-like vacuolar membrane staining (asterix). Expression of the GTPase mutants, K1347A or T1348N, markedly
disrupts FM4–64 vacuole localization with the appearance of multiple large punctate structures (arrows). (B) Quantification of endocytic trafficking
defect showing the average number of FM4–64-positive punctate structures per cell. A total of 100 cells were analyzed in one experiment and data are
representative of at least two independent experiments. Bars represent the mean 6 SEM. Data were analyzed for statistical significance by two-tailed
unpaired Student’s t-test relative to WT LRRK2, or by pair-wise comparisons with vector controls where indicated by horizontal lines (*P,0.01). n.s., non-
significant versus WT. (C) Frequency distribution showing the percent (%) of cells with different numbers of FM4–64-positive punctate structures as a
measure of endocytic trafficking defects between truncated LRRK2 GTPase variants. Data are taken from one experiment (n=100 cells) and are
representative of at least two independent experiments. (D) Yeast cells carrying LRRK2 GTPase variants have normal vacuolar morphology. DIC images
are employed to visualize the morphology of vacuoles for each LRRK2 construct following galactose induction and FM4–64 staining.
doi:10.1371/journal.pgen.1000902.g003
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(CPY) and alkaline phosphatase (ALP) proteins from the endo-
plasmic reticulum (ER) to the vacuole by pulse-chase analysis (data
not shown), which represent two distinct biosynthetic transport
pathways that converge upon the vacuole in addition to the
endocytic pathway. Notably, human a-synuclein expression in
yeast manifests prominent defects in normal CPY and ALP
trafficking consistent with derangements in ER-to-Golgi vesicular
trafficking [30]. Accordingly, toxicity induced by LRRK2 and
a-synuclein expression in yeast most likely occur via impairment of
distinct vesicular trafficking pathways.
GTPase Activity Modulates LRRK2-Induced Neuronal
Toxicity
In order to validate the observations from this yeast model of
LRRK2 toxicity and determine its wider applicability to mamma-
lian cells, we examined the effects of human LRRK2 domain
Figure 4. LRRK2 GTPase variants induce defects in autophagy. (A) Transmission electron micrographs demonstrating increased autophagic
vacuoles (asterix) within the vacuole of yeast cells expressing the toxic GTPase variants, K1347A or T1348N, in the LRRK2 GTP-COR-Kin fragment. V,
vacuoles; N, nucleus; Scale bars, 2 mm. (B) Quantification of autophagic defects showing the percentage of cells with autophagic vacuoles. A total of
100 cells were analyzed in one experiment and data are representative of at least two independent experiments. Bars represent the mean 6 SEM.
Data were analyzed for statistical significance by two-tailed unpaired Student’s t-test relative to WT LRRK2, or by pair-wise comparisons with vector
controls where indicated by horizontal lines (*P,0.01 and **P,0.001). n.s., non-significant versus WT.
doi:10.1371/journal.pgen.1000902.g004
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fragments and GTPase variants on neuronal viability. Expression
constructs containing LRRK2 fragments identical to those
employed in yeast including the GTPase domain (GTP), kinase
domain (Kin) and the GTP-COR-Kin fragment as well as full-
length WT or G2019S LRRK2 were individually co-transfected
together with eGFP as a marker into mouse primary cortical
neurons and their effects on neuronal viability were compared. A
well-established assay was employed to examine the viability of
eGFP-positive neurons containing LRRK2 based on neurite
process length and fragmentation as a reliable indicator of neuronal
viability [21,22,37,38]. Using this method, LRRK2 expression was
confirmed in .95% of eGFP-positive cortical neurons that were
also positive for the neuronal marker, MAP2 (representative images
in Figure S5A and S5C), and neuronal viability was also confirmed
by TUNEL staining (representative images in Figure S5B).
Expression of the GTPase domain, the GTP-COR-Kin fragment
and full-length WT LRRK2 induces significant and equivalent
neuronal toxicity relative to control neurons expressing eGFP alone,
with a 10–20% loss of viability (Figure 5A and 5B). The kinase
domain alone fails to significantly reduce neuronal viability. Full-
length LRRK2 containing the commonG2019S pathogenic variant
serves as a positive control for toxicity and induces a ,50% loss of
neuronal viability compared to control neurons (Figure 5A and 5B),
as previously reported [21–23,37].
Full-length human LRRK2 was packaged into a Herpes
Simplex Virus (HSV) amplicon that co-expresses eGFP to
generate an HSV-WT-LRRK2/CMV-eGFP amplicon. Expres-
sion of LRRK2 by the HSV amplicon causes similar neuronal
toxicity to that of full-length WT LRRK2 transiently co-
transfected into neurons with eGFP (Figure 5A and 5B), indicating
that transient transfection is a reliable and valid method by which
to assess LRRK2-induced toxicity. Thus, truncated LRRK2
proteins containing the GTPase domain produce similar neuronal
toxicity to that induced by full-length WT LRRK2 implying that
the GTPase domain may underlie the toxic effects of LRRK2.
To determine and compare the effects of truncated LRRK2
GTPase variants on neuronal viability, similar experiments were
conducted with the GTP-COR-Kin LRRK2 fragment containing
each mutation that was previously examined in the yeast model.
Expression of the GTPase-active WT, R1398L and RQ/TG
variants of LRRK2 induces a significant yet equivalent level of
neuronal toxicity relative to control neurons characterized by a
10–15% loss of viability (Figure 5C and 5D). Expression of the
LRRK2 GTPase-inactive variants, K1347A and T1348N, en-
hances neuronal toxicity compared to other GTPase variants with
a ,18% loss of viability for the K1347A variant and ,23% loss
for the T1348N variant that is significantly increased relative to
the WT protein (Figure 5C and 5D). Thus, GTPase variants in
truncated LRRK2 induce toxicity in neurons that closely parallel
their toxic effects in yeast. Collectively, these data demonstrate the
validity of the yeast model for accurately predicting the
detrimental effects of truncated LRRK2 variants on neuronal
viability. Taken together, these data reveal that alterations in
GTPase activity contribute to LRRK2-induced neuronal toxicity.
Expression of LRRK2 Causes Trafficking Defects in
Neurons
Since the LRRK2 yeast model indicates that truncated LRRK2
may function in vesicular trafficking pathways, including endocy-
tosis, the effect of full-length human LRRK2 on endocytosis and
exocytosis was monitored in primary neurons. Mouse hippocam-
pal neurons at days in vitro (DIV) 12 were transduced with HSV-
WT-LRRK2/CMV-eGFP or control virus and 48 hours later
synaptic vesicle (SV) endocytosis and exocytosis were monitored
by using the lipophilic fluorescent dye FM4–64. Neurons were first
exposed to FM4–64 in the presence of 90 mM KCl, which
depolarizes the nerve terminal and induces vesicular recycling and
subsequent loading of FM4–64 by SV endocytosis. SV exocytosis
was then monitored in real time by depolarizing the nerve
terminals to unload the FM4–64 dye. Based on comparison of the
mean fluorescence intensity values, the synaptic boutons of
neurons carrying HSV-WT-LRRK2/CMV-eGFP display an
approximate 1.34-fold decrease in loading of FM4–64 by
endocytosis compared to the HSV-PrPUC/CMV-eGFP control
(Figure 6A left panels, Figure 6B at time point ‘0’ sec, and
Figure 6C: control, 133.9965.897; WT LRRK2, 100.2367.098).
Following depolarization of the FM4–64-loaded SVs, the control
boutons displayed about 99% unloading of FM4–64 after 8 mins,
whereas the synaptic boutons overexpressing LRRK2 show
delayed unloading with an approximate 72% decrease in FM4–
64 signal (Figure 6A right panels, Figure 6B at time point ‘480’
secs, and Figure 6C: control, 0.88660.851; LRRK2, 28.360.804).
These data indicate that overexpression of full-length LRRK2
causes defects in both synaptic vesicle endocytosis and exocytosis
in neurons consistent with the observation that overexpression of
truncated LRRK2 variants in yeast perturbs vesicular trafficking
pathways.
A Genome-Wide Genetic Screen Identifies Modifiers of
LRRK2 Toxicity in Yeast
To define mechanisms underlying LRRK2-induced cytotoxicity
in yeast, we performed an unbiased genome-wide genetic screen to
identify yeast genes that could suppress or enhance toxicity. A
similar approach has been effective at identifying modifiers of a-
synuclein or mutant huntingtin toxicity in yeast [39]. We mated a
haploid query strain, harboring the galactose-inducible WT
LRRK2 GTP-COR-Kin fragment, to a collection of ,4,850
viable yeast deletion mutants. Following sporulation and haploid
mutant selection, we isolated deletion mutants that suppressed or
enhanced LRRK2 toxicity. Of 4,850 mutants screened, we
identified 2 gene deletions that enhanced LRRK2 toxicity
(Figure 7A, Table 1) and 7 deletions that suppressed toxicity
(Figure 7B, Table 1). Furthermore, these 7 LRRK2 toxicity
suppressors also suppressed toxicity induced by the LRRK2
mutants, K1347A and T1348N, in the GTP-COR-Kin fragment
(Figure 7C). This set of yeast genes that modify LRRK2
cytotoxicty function in a number of diverse pathways including
transcriptional regulation (AHC1 (GenBank #CAA99213) and
GCN4 (GenBank #AAA34640)), MAP kinase signaling (SLT2
(GenBank #AAB68912), small GTPase signaling (GCS1 GenBank
#CAA98805) and mitochondrial function (CCE1 GenBank
#AAB24906) (Table 1).
To further determine if these genetic modifiers enhance or
suppress LRRK2 toxicity by modifying trafficking defects in
yeast, we performed the FM4–64 assay in the two enhancer
deletion mutants carrying WT GTP-COR-Kin fragment and the 7
suppressor deletion mutants carrying the most toxic LRRK2
mutant, T1348N. Interestingly, both enhancer mutants promote
the endocytic trafficking defect induced by WT LRRK2 with an
increase in the appearance of labeled punctate structures (Figure 7D)
while the 7 suppressor mutants at least partially rescue the T1348N
LRRK2-induced endocytic trafficking defect with the appearance
of normal vacuolar membrane staining and a decrease in punctate
structures (Figure 7E). These data suggest that the genetic modifiers
can at least partially modulate vesicular trafficking pathways and
genetically interact with LRRK2 to modify LRRK2-induced
toxicity. Accordingly, these data suggest that vesicular trafficking
defects in yeast underlie, in part, LRRK2-induced toxicity.
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Figure 5. GTPase activity modulates LRRK2-induced neuronal toxicity. (A) Human LRRK2 domain fragments containing the GTPase domain
(GTP and GTP-COR-Kin) but not the kinase domain (Kin) alone induce neuronal toxicity similar to full-length WT LRRK2. Representative fluorescent
images (eGFP) showing mouse primary cortical neurons co-transfected with LRRK2 constructs and eGFP in a 10:1 molar ratio or transduced with
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Discussion
Here, we employ yeast cells to provide insight into the
pathobiology of human LRRK2, a protein that is associated with
autosomal dominant PD. A number of important conclusions can
be derived from this yeast model. First, expression of LRRK2
fragments containing the GTPase domain markedly reduces the
viability of yeast cells relative to other protein domains of LRRK2.
The expression of full-length LRRK2 in yeast is problematic since
it is highly insoluble and is sequestered into large cytoplasmic
inclusions, which prevents its potential for inducing toxicity.
Thus, it is only possible to develop a yeast model of LRRK2
Figure 6. Expression of LRRK2 causes vesicular trafficking defects in neurons. (A) Hippocampal neuronal synapses transduced with HSV-
WT-LRRK2/CMV-eGFP or HSV-PrPUC/CMV-eGFP as a control following FM4–64 dye loading by synaptic vesicle endocytosis and unloading by synaptic
vesicle exocytosis. Arrows indicate synaptic boutons. (B) Dynamic real-time quantification of FM4–64 fluorescence intensity in synaptic boutons
following dye loading and unloading over a 10 min period. Notice reduced initial loading and delayed release of the FM dye due to WT LRRK2
expression (C) Quantification of FM4–64 fluorescence intensity in synaptic boutons following dye loading at time point 0 sec and unloading at time
point 480 sec. Data represent the mean 6 SEM from three independent experiments (15 boutons for each experiment). Data were analyzed for
statistical significance by two-tailed unpaired Student’s t-test between HSV-FL-LRRK2 neurons and HSV-GFP control neurons (*P,0.01).
doi:10.1371/journal.pgen.1000902.g006
HSV-WT-LRRK2/CMV-eGFP virus expressing full-length WT LRRK2. Neuronal viability was analyzed at 48 hrs post-transfection (DIV 12) with non-viable
neurons exhibiting obvious neurite process and/or nuclear fragmentation (arrows). (B) Quantification of neuronal viability induced by LRRK2
expression. Bars indicate the viability of eGFP-positive neurons (n= 200) for each transfection condition expressed as a percent (%) of control neurons
(eGFP only). Data represent the mean 6 SEM from three independent experiments. Data were analyzed for statistical significance by two-tailed
unpaired Student’s t-test compared to control neurons (*P,0.01 and **P,0.001). n.s., non-significant. (C) LRRK2 GTPase variants (in GTP-COR-Kin
fragment) induce neuronal toxicity. Representative fluorescent images (eGFP) of neurons at 48 hrs post-transfection containing truncated LRRK2
GTPase variants and eGFP. Arrows indicate non-viable neurons. (D) Quantification of neuronal viability induced by truncated LRRK2 GTPase variants.
Bars indicate the viability of eGFP–positive neurons (n=200) for each transfection condition expressed as a percent (%) of control neurons (eGFP
only). Data represent the mean 6 SEM from three independent experiments. Data were analyzed for statistical significance by two-tailed unpaired
Student’s t-test compared to control neurons, or by pair-wise comparisons where indicated by horizontal lines (*P,0.05 and **P,0.005). n.s., non-
significant versus control.
doi:10.1371/journal.pgen.1000902.g005
GTPase Activity and LRRK2 Toxicity
PLoS Genetics | www.plosgenetics.org 10 April 2010 | Volume 6 | Issue 4 | e1000902
GTPase Activity and LRRK2 Toxicity
PLoS Genetics | www.plosgenetics.org 11 April 2010 | Volume 6 | Issue 4 | e1000902
pathobiology based upon protein domain fragments rather than the
full-length protein. Second, consistent with a prominent role for the
GTPase domain in mediating the toxic effects of LRRK2 in yeast,
the viability of yeast cells can be modulated by alterations in
GTPase activity due to several functional mutations. Notably,
interfering with GTPase activity (i.e. GTP hydrolysis) but not GTP
binding or kinase activity is sufficient to modify LRRK2-induced
toxicity in yeast. The pathogenic mutants R1441C/G and Y1699C
in full-length LRRK2 have significantly decreased GTPase activity
consistent with the notion that reduced GTPase activity is toxic to
cells. Importantly, however, pathogenic mutations associated with
familial PD (i.e. R1441C and G2019S) do not influence the toxicity
induced by truncated human LRRK2 in yeast which perhaps
suggests that these mutations may only exert their deleterious effects
in the context of full-length LRRK2 or in mammalian cells. Third,
the expression of functional LRRK2 GTPase variants induce
defects in the endocytic vesicular trafficking and autophagy
pathways. Vesicular trafficking and autophagic defects closely
correlate with the level of toxicity induced by each truncated
GTPase variant suggesting that defects in trafficking may underlie
LRRK2-induced toxicity in this model. Accordingly, genetic
modifiers that suppress LRRK2 toxicity in yeast also suppress
trafficking defects. Fourth, known suppressors of a-synuclein-
induced cytotoxicity in yeast do not suppress LRRK2 toxicity
suggesting that both proteins mediate their toxic effects through
distinct trafficking pathways yet with the common outcome of
impairing vesicular transport to the vacuole, the yeast equivalent of
the mammalian lysosome. Thus, defects in vacuolar or lysosomal
transport may commonly underlie the pathogenic effects of a-
synuclein and LRRK2. Fifth, the toxic effects of truncated LRRK2
GTPase variants are similar between yeast and neuronal models of
LRRK2 pathobiology and truncated or full-length LRRK2 cause
similar endocytic trafficking defects in both yeast cells and neurons,
respectively, suggesting that the yeast LRRK2model is predictive of
mammalian cells. Finally, a genome-wide genetic screen identified
potent modifiers of LRRK2 toxicity in yeast, which may provide
novel clues to the underlying mechanism of LRRK2-induced
toxicity.
Neuronal toxicity induced by WT and pathogenic variants of
full-length human LRRK2 critically requires intact GTP binding
Table 1. Yeast deletion strains synthetically sick with truncated LRRK2 or suppressors of the toxicity induced by truncated LRRK2.
Strain Homolog
Synthetically sick
or suppressor Function
ahc2D No Synthetically sick Putative transcriptional regulator; proposed to be an Ada Histone acetyltransferase complex component
rmd8D No Synthetically sick Cytosolic protein required for sporulation; Required for Meiotic nuclear Division
gcn4D No Suppressor Basic leucine zipper (bZIP) transcriptional activator of amino acid biosynthetic genes in response to amino acid
starvation
ade16D No Suppressor Enzyme of ‘de novo’ purine biosynthesis containing both 5-aminoimidazole-4-carboxamide ribonucleotide
transformylase and inosine monophosphate cyclohydrolase activities
yhl005cD No Suppressor Unknown ORF, Dubious ORF
slt2D Yes Suppressor Serine/threonine MAP kinase involved in regulating the maintenance of cell wall integrity and progression
through the cell cycle; regulated by the PKC1-mediated signaling pathway
gfd2D No Suppressor Identified as a high-copy suppressor of a dbp5 (Dead Box protein) mutation
cce1D No Suppressor Mitochondrial cruciform cutting endonuclease, cleaves Holliday junctions formed during recombination of
mitochondrial DNA
gcs1D Yes Suppressor ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1), involved in ER-Golgi transport; shares functional
similarity with Glo3p
The homolog category indicates yeast genes with clear human homologs.
doi:10.1371/journal.pgen.1000902.t001
Figure 7. A genome-wide genetic screen identifies modifiers of LRRK2 toxicity in yeast. (A) Yeast gene deletion strains ahc2D and rmd8D
markedly enhance LRRK2-induced toxicity in yeast compared to the WT strain. Yeast WT strain BY4741 and gene deletion strains ahc2D and rmd8D
cells were transformed with galactose-inducible expression constructs containing the central GTP-COR-Kin fragment of WT LRRK2 or empty vector as
a control. (B) Yeast gene deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1D suppress LRRK2-induced toxicity in yeast compared
to the WT strain. Yeast WT strain BY4741 and gene deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1D cells were transformed
with galactose-inducible expression constructs containing the central GTP-COR-Kin fragment of WT LRRK2 or empty vector as a control. (C) Yeast
gene deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1Dmarkedly suppress LRRK2 mutant K1347A and T1348N-induced toxicity
in yeast compared to the WT strain. Yeast WT strain BY4741 and gene deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1D cells
were transformed with galactose-inducible expression constructs containing K1347A and T1348N mutations in the central GTP-COR-Kin fragment of
LRRK2 or empty vector as a control. Spotting experiments were conducted to examine the viability of yeast cells due to the expression of the LRRK2
fragment (A–C). Shown are five-fold serial dilutions (from left to right, as indicated by graded open box) starting with equal numbers of cells grown
on media containing glucose (LRRK2 Off, left panel) or galactose (LRRK2 On, right panel). (D) Endocytosis of FM4–64 (red) was employed to monitor
vesicular trafficking in yeast gene deletion strains ahc2D and rmd8D carrying the WT LRRK2 GTP-COR-Kin fragment. WT yeast cells expressing the
GTP-COR-Kin fragment display normal ring-like vacuolar membrane staining (asterix) in addition to some punctate structures (arrow). Yeast gene
deletion strains ahc2D and rmd8D expressing the GTP-COR-Kin fragment markedly disrupts FM4–64 vacuole localization with the appearance of
multiple large punctate structures (arrows) whereas the ahc2D and rmd8D strains alone show normal vacuole staining. (E) Endocytosis of FM4–64
(red) was employed to monitor vesicular trafficking in yeast gene deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1D carrying
the LRRK2 GTP-COR-Kin mutant T1348N. WT yeast cells expressing the T1348N mutant display multiple large punctate structures (arrows). Yeast gene
deletion strains gcn4D, ade16D, yhl005cD, slt2D, gfd2D, cce1D, and gcs1D carrying the mutant T1348N generally exhibit normal ring-like vacuolar
membrane staining and a decrease in punctate structures.
doi:10.1371/journal.pgen.1000902.g007
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and kinase activity [21–23]. However, it has not yet been possible
to distinguish, which, if any, of these activities actually mediates
the downstream toxic effects of LRRK2 or whether they serve to
auto-regulate an alternative function or effector domain of this
protein. In yeast cells, the detrimental effects of expressing
truncated LRRK2 variants are independent of kinase activity
and are not influenced by two common pathogenic variants
located either in the GTPase domain (i.e. R1441C) or the kinase
domain (i.e. G2019S). Instead, toxicity is dependent on GTP
hydrolysis activity, but not GTP binding activity. In the context of
the central GTP-COR-Kin fragment of LRRK2 that is used here
to explore the effects of GTPase variants, mutations that impair
GDP/GTP binding and are thus GTPase-inactive promote
toxicity, whereas mutations that produce a hyperactive GTPase
partially reduce the toxic effects of LRRK2 (Figure 8). The lack of
effect of kinase activity or pathogenic mutations on yeast toxicity
induced by truncated human LRRK2, might suggest that they
require the full-length protein or a mammalian cellular context to
exert their effects on LRRK2-induced toxicity.
In the context of full-length LRRK2, the K1347A and T1348N
mutations prevent GTP binding and are GTPase-inactive but also
impair kinase activity, which partially prevents LRRK2-induced
neuronal toxicity [14,15,19–23]. The RQ/TG mutation produces
a Ras-like GTPase that also has impaired kinase activity owing to
its increased turnover of GTP [15,40], a feature reflected in our
yeast model. The R1398L mutation also promotes GTP hydrolysis
and accordingly we observe that introduction of this mutation into
full-length LRRK2 produces a kinase-inactive variant (data not
shown). The effects of the hyperactive GTPase mutants, RQ/TG
and R1398L, on neuronal toxicity induced by full-length LRRK2
have not been defined, but they are likely to be protective due to
their impairment of kinase activity and enhancement of GTPase
activity. Both R1398L and RQ/TG mutants are capable of
hydrolyzing GTP but their affinity for binding to GTP is reduced
suggesting that they most likely predominate in a GDP-bound
inactive state. It is likely that GTPase-inactive variants of LRRK2
induce greater toxicity in yeast through a novel gain-of-function
mechanism by interfering with a pathway or process, or sequestering
one or more proteins, critical for yeast survival or growth. A
dominant-negative mechanism for LRRK2-induced toxicity is
unlikely since yeast do not contain an obvious ortholog of human
LRRK2. While the truncated LRRK2 protein used herein does not
behave in a manner identical to full-length protein with regards to
the regulation of cytotoxicity in yeast or neurons, it instead reveals a
fundamental contribution of the GTPase domain and particularly
GTP hydrolysis activity in mediating the toxic effects of LRRK2. A
major challenge in future experiments will therefore involve
dissecting the precise contribution of GTPase activity, vesicular
trafficking pathways and genetic modifiers to neuronal toxicity
induced by full-length LRRK2 variants.
The fact that LRRK2 kinase activity plays no role in yeast
toxicity allowed us to reveal instead a major role for the GTPase
domain in toxicity induced by truncated LRRK2 in both yeast and
neurons. Fragments of other disease-causing gene products, such
as in Huntington’s disease or other poly-glutamine repeat
disorders [41–44], TDP-43opathies [45,46] and a-synucleinopa-
thies [47,48] play prominent roles in neurodegeneration due to the
pathogenic generation of these truncated proteins. Interestingly,
putative truncation fragments containing the LRRK2 GTPase
domain have been identified in PD brains [3,49]. In addition,
E1874stop is a LRRK2 pathogenic mutation in which the protein
lacks the kinase and WD40 domains [50]. Thus, understanding
whether GTPase domain-containing truncated LRRK2 proteins
are important for disease pathogenesis and how the GTPase
domain modulates full-length LRRK2 activity are important
avenues of investigation. Moreover, since the truncated GTPase
domain-containing LRRK2 constructs are toxic in the absence of
kinase activity, caution may be warranted by solely focusing on
Figure 8. GTPase activity plays a key role in the pathobiology of LRRK2. GTP hydrolysis activity but not GTP binding or kinase activity is
sufficient to modify toxicity induced by truncated human LRRK2 variants. Truncated GTPase variants with impaired GTP hydrolysis induce marked
defects in the endocytic vesicular trafficking and autophagy pathways, which may underlie LRRK2-induced toxicity. Truncated GTPase variants with
enhanced GTPase activity show reduced LRRK2-induced toxicity. Lines with arrows indicate promoting or activating effects while lines with blunt
ends indicate inhibitory effects.
doi:10.1371/journal.pgen.1000902.g008
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kinase inhibition as a therapeutic target for preventing LRRK2-
induced neurodegeneration. Indeed, the GTPase-inactive K1347A
mutant in the context of the full-length G2019S LRRK2 protein
only partially rescues LRRK2 toxicity despite completely inhibiting
kinase activity suggesting that perturbations in the GTPase domain
may have deleterious consequences in the setting of full-length
LRRK2 independent of kinase activity [21].
The mechanism by which truncated human LRRK2 is toxic to
yeast is unclear. The GTPase domain would appear to play a key
role in mediating toxicity but other protein domains may also
contribute. LRRK2-induced defects in endocytic vesicular traffick-
ing and autophagy may underlie toxicity in yeast, an observation
supported by the actions of genetic modifiers of toxicity on vesicular
trafficking. Consistent with the yeast LRRK2 model, full-length
LRRK2 causes defects in synaptic vesicle endocytosis and exocytosis
in neurons. Many other observations suggest that full-length
LRRK2 may play a role in vesicular trafficking in mammalian
neurons. LRRK2 is localized exclusively to a wide range of vesicular
and membranous structures in neurons, including lysosomes,
endosomes, multivesicular bodies, the ER, Golgi, mitochondria
and microtubule transport vesicles [51,52]. The G2019S variant
promotes the formation of LRRK2-positive axonal inclusions in
neurons that are membrane-bound and contain swollen lysosomes,
distended mitochondria associated with vacuoles, multivesicular
bodies and disrupted cytoskeletal components [24], perhaps
suggestive of disruption of normal vesicular trafficking.
Consistent with our studies, a potential role for LRRK2 in
endocytosis has recently been described [53]. LRRK2 interacts
and co-localizes with Rab5B on synaptic vesicles. Knockdown or
over-expression of LRRK2 in rodent primary neurons impairs
synaptic vesicle endocytosis that can be rescued by over-expression
of Rab5B [53], a GTPase involved in the early endocytic pathway
from plasma membrane to early endosome. Studies in C.elegans
with the human LRRK2 homolog, LRK-1, reveal a role for this
protein in regulating the proper transport of synaptic vesicles to
axonal regions possibly by acting at the trans-Golgi network to sort
vesicles away from an alternative dendrite-specific transport
mechanism [54]. Thus, in yeast it is likely that truncated LRRK2
interferes with the endocytic trafficking and autophagic pathways
through functionally interacting or competing with key proteins
involved in as yet unspecified steps during the transport of vesicles
or their protein cargo from the plasma membrane and/or
autophagosomes to the vacuole.
LRRK2-associated neurite shortening induced by the G2019S
variant may be mediated at least in part by autophagy, since it is
associated with the development of autophagic vacuoles and can be
reversed by impairing autophagy and potentiated by activating
autophagy [55]. In yeast, macroautophagy constitutes an additional
pathway for vacuolar transport involving the formation and delivery
of large double-membrane vesicles termed autophagosomes con-
taining cytoplasmic constituents and organelles to the vacuole for
degradation and recycling. The macroautophagy pathway is also
perturbed in our yeast LRRK2 model in addition to the endocytic
vesicular trafficking pathway. Consistent with our studies, a
potential role for LRRK2 in the endosomal-autophagic pathway
has recently been described [56]. Collectively, the observations from
neuronal and yeast models tend to support a role for LRRK2 in
regulating the sorting or transport of vesicles via endocytosis or
autophagic pathways that possibly converge on the vacuole/
lysosome (Figure 8). Further study of the biology and pathobiology
of LRRK2 in regulating vacuolar/lysosomal function and dynamics
may prove particularly insightful. In particular, it will be important
to clarify whether derangements in endocytic and autophagic
trafficking pathways critically underlie the neuronal toxicity induced
by disease-associated full-length LRRK2 variants and the mecha-
nism(s) involved in this pathologic process.
The observation that GTPase activity plays a key role in
LRRK2 toxicity may prove highly useful in dissecting the
molecular mechanism(s) underlying LRRK2-induced cytotoxicity
and in the identification of genes or small molecules that can
directly or indirectly modulate the GTPase activity of LRRK2.
The relevance of such an approach would be to identify modifiers
of GTPase activity that would additionally prevent kinase
activation as an alternative novel strategy to inhibit the pathogenic
effects of LRRK2. The key demonstration that truncated LRRK2
variants have similar effects on the viability of both yeast and
neuronal cells suggests that this yeast LRRK2 model could be
predictive for identifying genetic and chemical modifiers of
conserved pathways, processes or proteins that are relevant for
LRRK2-induced toxicity in neuronal models including human
neuronal models derived from iPS cells.
Our genome-wide genetic screen to identify suppressors and/or
synthetic sick or lethal interactions of LRRK2-induced toxicity in
yeast identified modifiers in a number of diverse pathways including
genes that are involved in transcriptional regulation, MAP kinase
signaling, small GTPase signaling and mitochondrial function.
These genes may play important roles in the pathobiology of
LRRK2-linked PD. Notably, two of the deletion suppressors have
human homologs. SLT2 has four human homologs, which are
serine/threonineMAP kinases MAPK1, 3, 11 and 14 involved in the
initiation of translation, meiosis, mitosis, and postmitotic functions in
differentiated cells. In addition they mediate their response via
activation by environmental stress, pro-inflammatory cytokines and
lipopolysaccharide by phosphorylating a number of substrates. The
human homolog of GCS1 is ADP-ribosylation factor GTPase
activating protein 1 (ARFGAP1) which plays a role in membrane
trafficking and/or vesicle transport. These deletion suppressors may
prove to be attractive drug targets and they may provide important
insight into the function of LRRK2.
In summary, our results provide evidence that the GTPase
domain may contribute to LRRK2-induced toxicity, with enhanced
GTP hydrolysis leading to reduced LRRK2 toxicity and impaired
GTP hydrolysis leading to enhanced LRRK2 toxicity. In addition,
our identification of genetic modifiers of LRRK2-induced toxicity in
yeast provides important clues to proteins or pathways that may
play key roles in mediating LRRK2-induced toxicity in higher
organisms.
Materials and Methods
Ethics Statement
All procedures involving animals were approved by and
conformed to the guidelines of the Institutional Animal Care
Committee of Johns Hopkins University.
Yeast Strains and Genetic Procedures
Yeast haploid strain BY4741 (MATa, his3D1, leu2D0, met15D0,
ura3D0) obtained from Open Biosystems (Huntsville, AL) was used
throughout this study. For the yeast genetic screen, the LRRK2
query strain was constructed in Y7092 (MATa, can1D::STE2pr-
Sp_his5, lyp1D, his3D1, leu2D0, ura3D0, met15D0). Yeast manipu-
lations were performed and media were prepared using standard
procedures. Transformations of yeast were performed using a
standard high efficiency lithium acetate procedure [57]. Yeast cells
carrying galactose-inducible expression constructs were routinely
grown in YPD or synthetic complete media lacking uracil (SC-
URA) containing glucose (2% dextrose) to repress the GAL1
promoter. Yeast cells were pre-grown in SC-URA containing 2%
GTPase Activity and LRRK2 Toxicity
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raffinose (no repression of the GAL1 promoter) prior to growth in
medium containing 2% galactose (to induce the GAL1 promoter),
to allow rapid, synchronous induction of expression. Yeast cells
that were co-transformed with two galactose-inducible constructs
(with URA3 or LEU2 markers) were grown in SC-URA/-LEU to
select for both plasmids.
Plasmid Generation and Antibodies
Human LRRK2 fragment cDNAs were amplified from a
pcDNA3.1-LRRK2-Myc-His vector [18] by PCR with primer
pairs specific for the different domains of LRRK2 (refer to
Figure 1A) with incorporation of an optimal yeast Kozak sequence
(AAAAATGTCT) surrounding an ATG start codon (underlined).
PCR products were first cloned into the pCR2.1-TOPO TA
cloning vector (Invitrogen, Carlsbad, CA) before subcloning into
the GAL1 promoter-based yeast expression vector pYES2/CT (2 m
ori, URA3; Invitrogen) or p416GAL (CEN ori, URA3; kindly
provided by Martin Funk [58]) containing a C-terminal V5 tag, or
into mammalian expression vector pcDNA3.1-Myc-His (Invitro-
gen) via BamHI and XhoI restriction sites. Missense mutations were
introduced into the GTP-COR-Kin fragment of LRRK2 by PCR-
mediated, site-directed mutagenesis, using the QuickChange XL
kit (Stratagene), followed by sequencing of the entire cDNA to
confirm their correct incorporation. Candidate genes (YPT1, YKT6
and HSP31) were amplified from yeast genomic DNA by PCR to
also introduce a C-terminal V5 tag and stop codon, and resulting
cDNAs were cloned into the GAL1 promoter-based yeast
expression vector p425GAL (2 m ori, LEU2, kindly provided by
Martin Funk [58]. All cDNAs were subjected to DNA sequencing
to confirm their integrity.
Mouse monoclonal antibodies to yeast 3-phosphoglycerate kinase
(PGK, clone 22C5), anti-V5 and anti-V5-HRP were obtained from
Invitrogen. Mouse monoclonal anti-myc antibody (clone 9E10) was
purchased from Roche Biochemicals. Rabbit polyclonal anti-GFP
antibody (NB 600-303) was obtained from Novus Biologicals. HRP-
linked anti-rabbit or anti-mouse IgG antibodies were obtained from
Jackson ImmunoResearch Labs (West Grove, PA). AlexaFluor-488
anti-mouse IgG and AlexaFluor-594 anti-rabbit IgG antibodies
were from Molecular Probes. Human LRRK2-specific antibody
JH5517 has been described previously [18,59].
Yeast Cell Viability Assays.
Spotting experiments. Cells carrying galactose-inducible
expression constructs were grown overnight at 30uC in liquid
media (SC-URA or SC-URA/-LEU) containing raffinose to log
phase, followed by growth in media containing galactose for a
further 6 hrs. Cultures were then normalized for OD600 nm,
serially diluted (5-fold) and spotted onto plates containing solid
media (SC-URA or SC-URA/-LEU) with either glucose or
galactose as the sole carbon source. Cells were grown at 30uC for
at least 2 days before imaging.
Growth curves: Cells were grown overnight in synthetic medium
(SC-URA or SC-URA/-LEU) containing raffinose and then
diluted to an OD600 nm of 0.1 before inducing expression in
media by addition of galactose. OD600 nm measurements were
taken at indicated time points over 18 hrs.
Reverse-Transcription (RT)–PCR
Yeast cells carrying galactose-inducible LRRK2 constructs were
grown and induced as described for spotting experiments. Total
RNA was isolated from yeast cells by hot phenol extraction [60]
and further purified using the Qiagen RNEasy Mini kit (Qiagen).
Total RNA concentrations were determined with a Nanodrop
spectrophotometer (Nanodrop Technologies) prior to RT-PCR.
cDNAs were generated from total RNA using the OneStep RT-
PCR kit (Qiagen) and oligo-d(T). PCR was conducted on equal
quantities of mRNA-derived cDNAs for 25 cycles with LRRK2-
specific primers located within the kinase domain (Forward: 59-
CCAGATCAACCAAGGCTCAC-39, Reverse: 59-CCTGCTG-
TTGTGATGTGTAG-39) or yeast actin (ACT1) primers (For-
ward: 59-TCGATTTGGCCGGTAGAGATT-39, Reverse: 59-
AAGATGGAGCCAAAGCGGTGATT-39) as a loading control.
GTP Binding Assay
Yeast cells carrying galactose-inducible LRRK2 constructs were
grown and induced as described for spotting experiments. Total
proteins were extracted from yeast by a standard method using
glass bead lysis. Briefly, yeast cells were pelleted and lysed in 1 ml
lysis buffer (1 X PBS, pH 7.4, 1% NP-40, 1 x phosphatase
inhibitor cocktail 1 and 2 [Sigma-Aldrich], 1 x Complete mini
protease inhibitor cocktail [Roche]) by vigorous shaking with glass
beads at 4uC for 15 min and lysates were clarified by
centrifugation at 17,5006g for 10 min at 4uC. Supernatants were
incubated with 50 ml c-aminohexyl-GTP-sepharose bead suspen-
sion (Jena Bioscience, Jena, Germany) by rotating at 4uC for 2 hr.
The sepharose beads were sequentially pelleted and washed twice
in wash buffer (1 X PBS, pH 7.4, 1% Triton X-100) and twice
with PBS alone. GTP-bound proteins were eluted into 50 ml
Laemmli sample buffer (BioRad) containing 5% 2-mercaptoeth-
anol by heating for 10 min at 95uC. GTP-bound proteins or input
controls (0.1% total lysate) were resolved by SDS–PAGE and
subjected to Western blot analysis with anti-V5 antibody. Bands
were visualized by enhanced chemiluminescence (Amersham).
Quantification of protein expression was performed using
densitometry analysis software (AlphaImager, Alpha Innotech
Corp.).
GTPase Activity Assay
GTP hydrolysis activity was measured by monitoring the release
of free c-phosphate (Pi) from GTP. Briefly, total proteins were
prepared from yeast cells carrying galactose-inducible LRRK2
constructs as described for GTP binding assays. Soluble lysates
were subjected to immunoprecipitation with anti-V5 antibody
(1 mg) pre-incubated with 50 ml Protein G Dynabeads (Invitrogen)
by rotating at 4uC overnight. Dynabeads were stringently washed
5x with lysis buffer before being subjected to GTPase activity assay
in 96-well plates using the colorimetric GTPase assay kit (Innova
Biosciences, Cambridge, UK) as per manufacturers instructions to
measure the concentration of free Pi with absorbance measured at
590–660 nm. LRRK2 immunoprecipitates (anti-V5) were also
analyzed by Western blot analysis with anti-V5 antibody to
quantify the input levels of each LRRK2 variant for normalization
purposes. Densitometric analysis was conducted on protein bands
using appropriate software (AlphaImager, Alpha Innotech Corp.).
A similar procedure was employed for myc-tagged full-length
human LRRK2 variants derived from HEK-293T cells to
measure LRRK2 GTPase activity.
HSV-LRRK2
The HSV amplicon platform was utilized to generate HSV-
LRRK2 expression vectors containing full-length human LRRK2
[61].
Transmission Electron Microscopy (TEM)
TEM was performed on yeast cells expressing truncated
LRRK2 variants as previously described [45,62] at the Integrated
Imaging Center, Johns Hopkins University.
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FM4–64 Assay in Yeast
Yeast cells carrying galactose-inducible LRRK2 constructs
were grown and induced as described for spotting experiments.
Following galactose induction for 6 hrs, 1 ml of culture was
harvested by brief centrifugation, resuspended in SC-URA media
containing galactose and 40 mM FM4–64 red fluorescent dye
(Molecular Probes) and incubated at 30uC for 20 minutes to allow
dye internalization by endocytosis. Cells were washed once in SC-
URA media containing galactose before being dispersed and
mounted onto microscope slides. Imaging of red fluorescence was
conducted on a Zeiss LSM510 live confocal system.
FM4–64 Assay in Neurons
Mouse primary hippocampal neurons (E15–16) were trans-
duced by HSV-WT-LRRK2/CMV-eGFP and HSVPrPUC/
CMV-eGFP virus at DIV 12. After 48 hour transduction, cells
were mounted in a laminar-flow perfusion chamber on the stage of
a custom-built laser scanning confocal microscope using a calcium
containing buffer (Solution B: 119 mM NaCl, 2.5 mM KCL,
4 mM MgCl2, 30 mM Glucose, 25 mM HEPES, 2 mM CaCl2).
After gently removing Solution B cells were then continuously
perfused with Solution A (Solution B without CaCl2). The first
stimulus was then applied with FM dye containing Solution D
(90 mM KCl, 29 mM NaCl, 2 mM CaCl2, 2 mMMgCl2, 30 mM
Glucose, 25 mM HEPES and 15 mM FM4–64, Molecular Probes)
for 2 min. This step leads to presynaptic release, vesicle fusion and
dye incorporation by synaptic vesicle endocytosis. Cells were then
washed by perfusion with Solution A for up to 10 min to minimize
background staining. After gently aspirating Solution A, Solution
C (Solution D without FM dye) is applied to cause release of the
FM dye by synaptic vesicle exocytosis. Images were acquired every
10 sec with a CCD camera. The fluorescence intensity of
manually designated pre-synaptic regions was quantified.
Primary Cortical Neuronal Cultures and Viability Assay
Primary cortical neuronal cultures were prepared and transiently
transfected with LRRK2 or eGFP expression constructs as de-
scribed previously [22,37]. Briefly, cortices were dissected from
embryonic day 15–16 fetal mice (CD1 strain), dissociated by a
12 min digestion in TrypLE (Invitrogen), and neurons were seeded
into 24-well plates coated with poly-L-ornithine. Neurons were
routinely maintained in Neurobasal media (Invitrogen) containing
2 mM L-glutamine and 2% B27 supplement at 37uC in a 7% CO2
humidified incubator. Glial cell growth was inhibited by addition of
5-fluoro-20-deoxyuridine (5F2DU, 30 mM, Sigma) to the media on
days in vitro (DIV) 4. Media was replaced once every third day. At
DIV 10, neurons represented.90% of total cells in the culture. To
assess LRRK2-induced toxicity, neurons at DIV 10 were transiently
co-transfected with LRRK2 and eGFP expression constructs at a
molar ratio 10:1, respectively, using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer recommendations. At
48 hrs post-transfection (DIV 12), live fluorescent images were
collected on a Zeiss Automatic stage microscope with Axiovision 6.0
software. Neurons with obvious neurite process and/or nuclear
fragmentation were counted as non-viable cells by investigators
blinded to the identity of the experiment. For each independent
experiment, the percent viability of eGFP-positive neurons (n=200)
was determined and data are presented as a percent of control
neurons transfected with eGFP alone. Neurons were subsequently
fixed with 4% paraformaldehyde and immunocytochemistry was
conducted with anti-myc (Roche) and anti-GFP (Novus Biologicals)
antibodies and appropriate fluorescent secondary antibodies.
LRRK2 expression was confirmed in .95% of eGFP-positive
neurons (Figure S5A).
TUNEL staining
The above transfected neurons were fixed in 4% paraformal-
dehyde (PFA) after 48 hrs transfection. TUNEL staining was
performed using the In Situ Cell Death Detection Kit (Roche) as
per the manufacturer’s instructions.
Immunocytochemistry
Yeast cells carrying galactose-inducible LRRK2 constructs were
grown and induced as described for spotting experiments.
Following galactose induction for 6 hrs, 1 ml culture was
harvested by brief centrifugation, and fixed in 4% formalde-
hyde/PBS for 1 hr. Cell walls were digested by incubation with
Zymolyase 20T solution (ICN Biochemicals), as recommended.
Following permeabilization, cells were gently washed twice in KS
solution (100 mM potassium phosphate pH 7.0, 1 M sorbitol),
and then resuspended in KS solution. Immunostaining with mouse
monoclonal anti-V5 antibody (Invitrogen) and AlexaFluor-488
anti-mouse IgG (Molecular Probes) was conducted as previously
described [63] Cells were dispersed onto microscope slides and
mounted using Vectashield mounting medium containing DAPI
(Vector Laboratories) for nuclear visualization. Fluorescent images
were collected on a Zeiss Automatic stage microscope with
Axiovision 6.0 software.
Yeast Genome-Wide Genetic Screen
The yeast LRRK2 toxicity modifier screen was performed using
synthetic genetic array (SGA) analysis [64] as previously described
[65]. We used a Singer RoToR HAD yeast pinning robot for
manipulating yeast colonies at high density. A MATa yeast
haploid query strain, Y7092, carrying WT LRRK2 GTP-COR-
Kin fragment was mated with a haploid yeast gene deletion
collection of 4850 viable mutants, sporulated and then underwent
selection for haploid mutants that also harbored the LRRK2
plasmid on solid media containing G418 and lacking uracil.
Haploid deletion mutants that also carried the LRRK2 plasmid
were identified on selectable media containing glucose and then
the expression of LRRK2 was induced by growth on galactose
media. After comparing colony sizes on galactose plates to those
on glucose plates and normalizing for differences in the growth of
deletion mutants between carbon sources, genes that suppressed or
enhanced LRRK2 toxicity were identified. Initial hits from the
screen were independently verified by fresh transformations and
spotting assays.
Supporting Information
Figure S1 Expression of full-length human LRRK2 in yeast
cells. (A) Cell viability assay was employed to analyze the effect of
high copy and low copy expression of full-length WT LRRK2 or
high copy expression of G2019S LRRK2 on yeast growth
compared to control cells (empty vector). Shown are five-fold
serial dilutions (from left to right, as indicated by graded open box)
starting with equal numbers of cells spotted onto glucose (LRRK2
Off, left panel) or galactose (LRRK2 On, right panel) media. (B)
Growth curve analysis in liquid media containing galactose was
used to measure the growth rate of yeast cells expressing full-length
LRRK2 variants or containing empty vector. (C) Expression of
full-length LRRK2 (WT or G2019S) in yeast cells was detected by
Western blot analysis (SDS-PAGE with 8% Urea) with LRRK2-
specific antibody (JH5517) on urea-soluble proteins extracted from
yeast following galactose induction for 6 or 12 hrs or just prior to
induction (0 hrs) in liquid media. Full-length human LRRK2
transiently expressed in HEK-293 cells was used as a positive
control. Note that full-length LRRK2 expressed in yeast cells is
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highly insoluble and accumulates at the top of the stacking gel
whereas LRRK2 expressed in HEK-293 cells migrates normally at
,260 kDa. (D) mRNA expression levels of full-length LRRK2 in
yeast cells were detected by RT-PCR with LRRK2-specific
primers and actin (ACT1) primers as a loading control. (E)
Immunofluorescent localization of full-length human LRRK2
(WT or G2019S) expressed in yeast cells. LRRK2 subcellular
localization was revealed by immunostaining cells with a human
LRRK2-specific antibody (JH5517) following galactose induction.
Arrows indicate large LRRK2-positive cytoplasmic inclusions that
are absent from control cells (empty vector).
Found at: doi:10.1371/journal.pgen.1000902.s001 (3.20 MB TIF)
Figure S2 Localization of truncated LRRK2 variants in yeast.
LRRK2 domain fragments (A) and LRRK2 GTPase functional
variants in the GTP-COR-Kin fragment (B) exhibit similar diffuse
cytoplasmic localization patterns in yeast cells. Fluorescence
microscopy was employed to visualize the subcellular localization
of each LRRK2 construct following galactose induction. Cells
were stained with anti-V5 antibody (green) and counterstained
with DAPI (blue) to label nuclei. The overlay of LRRK2 and
DAPI fluorescence is also indicated.
Found at: doi:10.1371/journal.pgen.1000902.s002 (14.70 MB
TIF)
Figure S3 Kinase-modifying mutations fail to influence
LRRK2-induced toxicity in yeast. Kinase-modifying mutations
were introduced into the kinase domain of the GTP-COR-Kin
LRRK2 fragment, including two pathogenic variants that enhance
kinase activity (G2019S and R1441C) and two kinase-impaired
mutations (K1906M and TripKIN [T2031A/S2032A/T2035A,
representing three putative autophosphorylation sites in the kinase
activation loop]). Cell viability assay was employed to examine the
effects of modulating kinase activity on the viability of yeast cells.
Shown are five-fold serial dilutions (from left to right, as indicated
by graded open box) starting with equal numbers of cells spotted
onto glucose (repressed, off, left panel) or galactose (induced, on,
right panel) media.
Found at: doi:10.1371/journal.pgen.1000902.s003 (1.34 MB TIF)
Figure S4 Candidate genetic screen for suppressors of LRRK2-
induced toxicity in yeast. (A) Cell viability assay for three candidate
genes (HSP31, YPT1, and YKT6) transformed either alone or
together with WT LRRK2 (GTP-COR-Kin fragment). Empty
vector was used as a control for viability. Shown are five-fold serial
dilutions (from left to right, as indicated by graded open box)
starting with equal numbers of cells spotted onto glucose
(repressed, LRRK2 Off, left panel) or galactose (induced, LRRK2
On, right panel) media. Below, Western blot analysis of total
proteins from each yeast transformant following galactose
induction probed with anti-V5 antibody to confirm the expression
of LRRK2 and each candidate interactor protein. (B) Cell viability
assay for three candidate genes co-transformed with LRRK2
GTPase variants, K1347A or T1348N, in the GTP-COR-Kin
fragment, compared to single transformation of LRRK2 alone or
empty vector as controls. Shown are five-fold serial dilutions (from
left to right, as indicated by graded open box) starting with equal
numbers of cells spotted onto glucose or galactose media.
Found at: doi:10.1371/journal.pgen.1000902.s004 (3.16 MB TIF)
Figure S5 Representative images demonstrating the co-expres-
sion of LRRK2 and eGFP, neuronal viability and confirmation of
neuronal type in the LRRK2-induced neuronal toxicity assay. (A)
LRRK2 is expressed in .95% eGFP-positive neurons when co-
transfected with eGFP into primary neurons at a molar ratio of
10:1. Neurons were co-stained by anti-MYC (LRRK2) and anti-
GFP antibodies after 48 hr co-transfection with LRRK2 and
eGFP plasmids. (B) Neuronal viability was confirmed by TUNEL
staining. Neurons were stained by TUNEL and with anti-GFP
antibody after 48 hr co-transfection of LRRK2 and eGFP. The
arrow indicates a non-viable eGFP-positive neuron expressing
G2019S LRRK2 that also exhibits a TUNEL-positive nucleus.
eGFP-positive neurons carrying empty vector or viable neurons
expressing G2019S LRRK2 are negative for nuclear TUNEL
staining. (C) Confirmation of LRRK2 expression in MAP2-
positive cortical neurons. Neurons were co-stained with anti-
MAP2 and anti-GFP antibodies after 48 hr co-transfection of
LRRK2 and eGFP plasmids at a 10:1 molar ratio. eGFP-positive
neurons expressing WT LRRK2 are positive for the neuronal
marker MAP2.
Found at: doi:10.1371/journal.pgen.1000902.s005 (18.51 MB
TIF)
Acknowledgments
We are grateful to Dr. Shaida A. Andrabi (Johns Hopkins) for valuable
technical advice and to Mr. Louis Lotta and Mr. Clark Burris (University
of Rochester) for HSV amplicon vector packaging assistance. The authors
thank J. Michael McCaffery at the Integrated Imaging Center and
Department of Biology, Johns Hopkins University, for assistance with
electron microscopy.
Author Contributions
Conceived and designed the experiments: YX CEC VLD DJM TMD.
Performed the experiments: YX AK XL ADG TMD. Analyzed the data:
YX CEC VLD DJM TMD. Contributed reagents/materials/analysis
tools: WJB VLD TMD. Wrote the paper: YX VLD DJM TMD.
References
1. Lang AE, Lozano AM (1998) Parkinson’s disease. Second of two parts.
N Engl J Med 339: 1130–1143.
2. Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med
339: 1044–1053.
3. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, et al. (2006) Biochemical
and pathological characterization of Lrrk2. Ann Neurol 59: 315–322.
4. Healy DG, Wood NW, Schapira AH (2008) Test for LRRK2 mutations in
patients with Parkinson’s disease. Pract Neurol 8: 381–385.
5. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of
the gene containing mutations that cause PARK8-linked Parkinson’s disease.
Neuron 44: 595–600.
6. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, et al. (2006)
Lrrk2 and Lewy body disease. Ann Neurol 59: 388–393.
7. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in
LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
Neuron 44: 601–607.
8. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, et al. (2005) A
common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365:
415–416.
9. Haugarvoll K, Wszolek ZK (2006) PARK8 LRRK2 parkinsonism. Curr Neurol
Neurosci Rep 6: 287–294.
10. Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, et al. (2007) The roles of
kinases in familial Parkinson’s disease. J Neurosci 27: 11865–11868.
11. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in
Parkinson’s disease: protein domains and functional insights. Trends Neurosci
29: 286–293.
12. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, et al. (2006) The
Parkinson disease causing LRRK2 mutation I2020T is associated with increased
kinase activity. Hum Mol Genet 15: 223–232.
13. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The
Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that
undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906–16914.
14. Guo L, Gandhi PN, WangW, Petersen RB, Wilson-Delfosse AL, et al. (2007) The
Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an
authentic GTPase that stimulates kinase activity. Exp Cell Res 313: 3658–3670.
15. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, et al. (2007) GTP binding is
essential to the protein kinase activity of LRRK2, a causative gene product for
familial Parkinson’s disease. Biochemistry 46: 1380–1388.
GTPase Activity and LRRK2 Toxicity
PLoS Genetics | www.plosgenetics.org 17 April 2010 | Volume 6 | Issue 4 | e1000902
16. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2
phosphorylates moesin at threonine-558: characterization of how Parkinson’s
disease mutants affect kinase activity. Biochem J 405: 307–317.
17. Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S (2007)
Mechanistic insight into the dominant mode of the Parkinson’s disease-
associated G2019S LRRK2 mutation. Hum Mol Genet 16: 2031–2039.
18. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005)
Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment
kinase activity. Proc Natl Acad Sci U S A 102: 16842–16847.
19. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C
mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun
357: 668–671.
20. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, et al. (2007) Leucine-rich
repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in
familial Parkinson’s disease R1441C/G mutants. J Neurochem 103: 238–247.
21. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, et al. (2006) Kinase
activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:
1231–1233.
22. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson’s
disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase
activities to neuronal toxicity. Hum Mol Genet 16: 223–232.
23. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase
activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol
Dis 23: 329–341.
24. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, et al. (2006) The
familial Parkinsonism gene LRRK2 regulates neurite process morphology.
Neuron 52: 587–593.
25. Liu Z, Wang X, Yu Y, Li X, Wang T, et al. (2008) A Drosophila model for
LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105: 2693–2698.
26. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, et al. (2009) Parkin protects
against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in
Drosophila. J Neurosci 29: 11257–11262.
27. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, et al. (2009)
Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a
Drosophila melanogaster model of Parkinson’s disease. Hum Mol Genet.
28. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2(R1441G)
BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat
Neurosci 12: 826–828.
29. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, et al. (2009)
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.
Proc Natl Acad Sci U S A 106: 14622–14627.
30. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, et al. (2006) Alpha-
synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s
models. Science 313: 324–328.
31. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, et al. (2008) The
Parkinson’s disease protein alpha-synuclein disrupts cellular Rab homeostasis.
Proc Natl Acad Sci U S A 105: 145–150.
32. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein
biology and pathobiology. Science 302: 1772–1775.
33. Wilson MA, St Amour CV, Collins JL, Ringe D, Petsko GA (2004) The 1.8-A
resolution crystal structure of YDR533Cp from Saccharomyces cerevisiae: a
member of the DJ-1/ThiJ/PfpI superfamily. Proc Natl Acad Sci U S A 101:
1531–1536.
34. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R (2008) LRRK2 is a
component of granular alpha-synuclein pathology in the brainstem of
Parkinson’s disease. Neuropathol Appl Neurobiol 34: 272–283.
35. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophys-
iology of Parkinson’s disease. Annu Rev Neurosci 28: 57–87.
36. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of
Parkinson disease: molecules to medicine. J Clin Invest 116: 1744–1754.
37. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, et al. (2005) Leucine-rich repeat
kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal
degeneration. Proc Natl Acad Sci U S A 102: 18676–18681.
38. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT (2009) The Parkinson
disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-
associated protein with death domain and caspase-8 in a cellular model of
neurodegeneration. J Neurosci 29: 1011–1016.
39. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (2003) Yeast
genes that enhance the toxicity of a mutant huntingtin fragment or alpha-
synuclein. Science 302: 1769–1772.
40. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, et al. (2008) Structure of the
ROC domain from the Parkinson’s disease-associated leucine-rich repeat kinase
2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105: 1499–1504.
41. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation
of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in
brain. Science 277: 1990–1993.
42. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ (2000) Amino-terminal
fragments of mutant huntingtin show selective accumulation in striatal neurons
and synaptic toxicity. Nat Genet 25: 385–389.
43. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, et al. (2002)
Proteases acting on mutant huntingtin generate cleaved products that
differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259–269.
44. Ross CA (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms
for Huntington’s disease and related disorders. Neuron 35: 819–822.
45. Johnson BS, McCaffery JM, Lindquist S, Gitler AD (2008) A yeast TDP-43
proteinopathy model: Exploring the molecular determinants of TDP-43
aggregation and cellular toxicity. Proc Natl Acad Sci U S A 105: 6439–6444.
46. Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, et al. (2007) Progranulin
mediates caspase-dependent cleavage of TAR DNA binding protein-43.
J Neurosci 27: 10530–10534.
47. Li W, West N, Colla E, Pletnikova O, Troncoso JC, et al. (2005) Aggregation
promoting C-terminal truncation of alpha-synuclein is a normal cellular process
and is enhanced by the familial Parkinson’s disease-linked mutations. Proc Natl
Acad Sci U S A 102: 2162–2167.
48. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, et al. (2003) Role
of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry
42: 8530–8540.
49. Miklossy J, Arai T, Guo JP, Klegeris A, Yu S, et al. (2006) LRRK2 expression in
normal and pathologic human brain and in human cell lines. J Neuropathol Exp
Neurol 65: 953–963.
50. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, et al. (2006) A
common missense variant in the LRRK2 gene, Gly2385Arg, associated with
Parkinson’s disease risk in Taiwan. Neurogenetics 7: 133–138.
51. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, et al. (2006) Localization of
LRRK2 to membranous and vesicular structures in mammalian brain. Ann
Neurol 60: 557–569.
52. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, et al. (2007) Leucine-rich
repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16: 678–690.
53. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, et al. (2008) LRRK2 regulates
synaptic vesicle endocytosis. Exp Cell Res 314: 2055–2065.
54. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N (2007)
LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity
of SV proteins. Curr Biol 17: 592–598.
55. Plowey ED, Cherra SJ, 3rd, Liu YJ, Chu CT (2008) Role of autophagy in
G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
J Neurochem 105: 1048–1056.
56. Alegre-Abarrategui J, Christian H, Lufino M, Mutihac R, Lourenco Venda L,
et al. (2009) LRRK2 regulates autophagic activity and localises to specific
membrane microdomains in a novel human genomic reporter cellular model.
Hum Mol Genet.
57. Gietz RD, Woods RA (2002) Transformation of yeast by lithium acetate/single-
stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350:
87–96.
58. Mumberg D, Muller R, Funk M (1994) Regulatable promoters of Saccharo-
myces cerevisiae: comparison of transcriptional activity and their use for
heterologous expression. Nucleic Acids Res 22: 5767–5768.
59. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, et al. (2007)
Localization of Parkinson’s disease-associated LRRK2 in normal and patholog-
ical human brain. Brain Res 1155: 208–219.
60. Schmitt ME, Brown TA, Trumpower BL (1990) A rapid and simple method for
preparation of RNA from Saccharomyces cerevisiae. Nucl Acids Res 18:
3091–3092.
61. Maguire-Zeiss KA, Bowers WJ, Federoff HJ (2001) HSV vector-mediated gene
delivery to the central nervous system. Curr Opin Mol Ther 3: 482–490.
62. Rieder SE, Banta LM, Kohrer K, McCaffery JM, Emr SD (1996) Multilamellar
endosome-like compartment accumulates in the yeast vps28 vacuolar protein
sorting mutant. Mol Biol Cell 7: 985–999.
63. Corbett M, Xiong Y, Boyne JR, Wright DJ, Munro E, et al. (2006) IQGAP and
mitotic exit network (MEN) proteins are required for cytokinesis and re-
polarization of the actin cytoskeleton in the budding yeast, Saccharomyces
cerevisiae. Eur J Cell Biol 85: 1201–1215.
64. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, et al. (2001)
Systematic genetic analysis with ordered arrays of yeast deletion mutants.
Science 294: 2364–2368.
65. Tong AH, Boone C (2006) Synthetic genetic array analysis in Saccharomyces
cerevisiae. Methods Mol Biol 313: 171–192.
GTPase Activity and LRRK2 Toxicity
PLoS Genetics | www.plosgenetics.org 18 April 2010 | Volume 6 | Issue 4 | e1000902
